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ABSTRACT 
Background: Quantification of the viral burden is an important laboratory tool in the management of hepatitis B virus 
(HBV)-infected patients. However, widespread use of assays is still hampered by the high cost. Treatment reduces 
viral load to undetectable levels. HBV infected patients tend to have high HBV DNA levels, and severe liver disease.  
Objectives: This study was carried out to determine the pattern of HBV viral load levels of patients assessing 
management in Nigeria.  
Method: Variables included sociodemographics like age, sex, religion, income, educational background and residence. 
The COBAS Amplicor automated Analyzer (PCR based) was used to assay the virus quantitatively. 
Results: 594 patients were tested from 2008 to 2009. Statistical analysis was done using Epi info version 2002 and test 
of significance by Kruskal-Wallis. Mean age of the patients was 36.8 (ranging from 9 to 69) years. HBV viral titre 
ranged between 4,145 and 68,011,800 DNA copies/ml. 
Conclusion: There was a high occurrence of viral titre in the population studied. High viral load is a risk factor for 
hepatocellular carcinoma. A policy earmarked to combat this virus in Nigeria is hereby solicited. 
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INTRODUCTION 
Viral hepatitis is as old as the history of medicine. 
About a third of the world's population, more 
than 2 billion people, have been infected with the 
hepatitis B virus [1]. Hepatitis B virus (HBV) 
infection is a public health problem with 350 
million chronic carriers worldwide. An estimated 
500,000 to 1.2 million people die of HBV infection 
annually. The global disease burden is 
substantial due to its high related morbidity and 
mortality.  
Prevalence varies greatly in different parts of the 
world, but is higher in tropical regions causing 
both acute and chronic liver disease [2]. In 
Nigeria, 11.6% prevalence rate has been reported 
from Maiduguri [3], 13.8% from Lagos [4], 4.3%  
 
from Port Harcourt [5], 5.7% from Ilorin [6], 8.3% 
from Zaria [7], 17.1% from female sex workers, 
14.9% [8] from healthy blood donors [9] and 25.7% 
among surgeons [10]. Although HBV prevalence 
varies widely across the African continent, 
hepatitis B surface antigen (HBsAg) positivity is 
estimated at 8-20% [11].  About 15-40% of HBV 
infected patients would develop cirrhosis, liver 
failure, or hepatocellular carcinoma (HCC) [12].  
Jatau et al while working on pregnant women 
showed that HBV infection increases with age to 
a level and decreases with higher age [13]. People 
with chronic hepatitis B virus infection who 
experience hepatitis B "e" antigen (HBeAg) 
seroconversion before age 30 have better long- 
 
term outcomes - including lower rates of 
cirrhosis and liver cancer - than those who 
seroconvert 10 years later [14].  The risk of primary 
liver cancer increases with age and alcohol 
consumption [15]. Influence of age on 
development of HBV carrier state has been 
studied and a consistent relation was found. 
A study by Chen et al showed a persistent 
suppression of HBV DNA is important to 
prevent the development of HCC in known 
cirrhosis patients [16]. Treatment with the 
interferon group reduces viral load to 
undetectable levels with a 50-70% success rate. 
HBV is classified into 8 genotypes, A-H.  
In Nigeria, centres where one can assess his or 
her hepatitis status are many, but for quantitative 
determinations, they are rare and expensive. 
Samples have previously been taken outside the 
country to foreign laboratories. This costly 
enterprise keeps the test out of reach of the 
average citizen. However, the HBV DNA test is 
essential to hepatitis B management.  
The purpose of this study was to present the 
pattern of HBV viral load levels of people in 
terms of age/sex distribution and zonal 
distribution in Nigeria.  
 
MATERIALS AND METHODS 
Data, sample collection and processing: A 
biodata was raised for each of the 594 subjects 
(age range 9 - 69 years) containing details of their 
age, sex and residential address. 5 ml of blood 





treated tubes and centrifuged for 10 minutes. The 
plasma was separated and stored at -20°C until 
analysed. Subjects had been previously 
confirmed HBsAg positive prior to assessing the 
HBV viral load test. 
Study design: This is a descriptive retrospective 
study. 
Sample population: This consists of five 
hundred and ninety four subjects, from all over 
Nigeria requesting HBV viral load test within 20 
months. The inclusion criteria were those that 
tested positive for HBsAg. Only the first test 
carried out by a patient was included in this 
study.  
Sample Analyses: This was carried out at the 
Human Virology unit of the Nigerian Institute of 
Medical Research, Lagos, Nigeria. 
HBV DNA viral load assay: Samples were 
assayed for the quantity of hepatitis B virus 
according to the COBAS Amplicor HBV monitor 
test (Roche diagnostics GmbH, Mannheim, 
Germany) manual, Version 2.0, a PCR based 
technique, at the Human Virology Unit, Nigerian 
Institute of Medical Research, Lagos, Nigeria. 
The HBV viral load results were expressed in 
DNA copies/ml, after converting from the IU/ml 
value reported by the automated analyzer. 
Statistical Analyses: This was done using Epi 
info version 2002 and test of significance using 
Kruskal-Wallis statistical packages. Differences of 
p<0.05 were taken to be statistically significant at 
95% confidence interval. 
 
RESULTS 
The age and sex distribution of the HBV viral 
load values are shown in table 1. It revealed a 
hepatitis B DNA range of 4,145-68,011,800 DNA 
copies/ml. Male to female ratio was 2.9:1 
respectively. The median HBV viral load for 
males and females were 10,941 and 10,257 DNA 
copies/ml respectively (P>0.005). The age bracket 
with the highest HBV prevalence was the 30–39 
age group.  
The steady increase in patient turn-out during 
the 20 month time period (ranging from 3-69 
patients/month) is shown in figure 1. 
Geographical distribution of subjects assayed 
shows the largest group coming from the south-
west of the country, 51.3%, followed by the 
south-east 12.2%, north-central and south-south 
with 10.3% and 8.8% respectively, as shown in 
table 2.  
 The test-turnaround-times (TAT) from first assay 
until December 2009 are shown in figure 2. Initial 
TAT was 55 days (requiring the lab to call 
patients for result pick-up), but it gradually 
improved to 10 days as sample size increased. Of 
the 594 subjects tested, 2 results were sent by 
email in 2008 and 36 in 2009. Number of 
unclaimed results was 3 in 2008 and 10 in 2009. 
Number of repeat testing was 11 in 2008 and 12 
in 2009.  
TABLE 1 
AGE AND SEX DISTRIBUTION OF OF 
PATIENTS AND THEIR HBV VIRAL 











0-9 1    (0.23) 68,011,800.0 0.0536 
10-19 19    (3.21) 4,145.0 
20-29 126  (24.28) 18,463.0 
30-39 223   (36.04) 8,100.0 
40-49 152   (24.11) 8,363.0 
50-59 53     (9.55) 17,331.5 
60-69 10     (1.91) 46,998.0 
Sex    
Male 441  (74.2) 10,941.0 0.3636 
Femal
e 
153  (25.8) 10,257.0 




ZONAL DISTRIBUTION OF SUBJECTS ASSAYED 




HBV viral load tests 
N   (%) 
NE 1   (0.2%) 
NW 3   (0.5%) 
NC 61 (10.3%) 
SS 52 (8.8%) 
SE 72 (12.2%) 
SW 305 (51.3%) 
Unknown 100 (16.9%) 
Total 594 (100%) 
 
DISCUSSION 
Infection with HBV is under control in developed 
countries [1], but it is still a serious public health 
problem in developing countries like Nigeria. In 
this study we examined the viral load pattern of 
those assessing laboratory services at our site, 





viral load is carried out commercially within the 
country. As such samples were received from a 
wide range of localities across the country (Table 
2). There was a wide age range observed by the 
patients, with the highest prevalence being 
between 30-39 years. This compares to what was 
observed by Jatau and colleagues [13], and Belo 
[10].  
 In this study also, more males requested the test 
than the female counterparts. This is in 
consonance with those observed in previous 
studies [4]. This pattern could be because of the 
higher purchasing power of men, as the test is 
expensive. There was a wide disparity in the viral 
titre amongst the age groups, but it was of no 









TEST-TURN-AROUND-TIME (TAT) PROFILE OF THE HBV VIRAL LOAD ASSAY  
 
*TAT is the average number of calendar days from sample collection to lab assay 
 
Since HBV viral load is an independent predictor 
of liver cancer risk, this points to the importance 
of both close clinical monitoring and antiviral 
treatment for individuals with high HBV viral 
load (>10, 000 copies/ml). The lower and upper 
limit of detection of the COBAS Hepatitis B 
monitor assay used was 316 and 199,880 DNA 
copies/ml respectively. HBV viral load may be 
seen as a good surrogate marker for slower 
clinical progression. The risk of HCC is closely 
associated with HBV, according to a Taiwanese 
study [17]. This association was shown to be 
independent of other risk factors, and to have a 
dose-response relationship. That study also 
showed that HBV DNA levels were persistently 
elevated in patients at highest risk of liver cancer 
[12]. There is therefore a high a risk of 
hepatocellular carcinoma among this population 
studied because of the high viral load observed. 
However this could be averted if regular/routine 
screening of the populace is in place. This risk 
could be minimized if the National programme 
on immunization (NPI) scheme for HBV 
vaccination is implemented. This study, again 
confirms the previously reported high prevalence 
of HBsAg in this part of the world [5]. Patients 
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infected with HBV, treated with peg-
interferon2alfa and lamivudine are more likely to 
have a sustained virologic response [19].  
The challenges of carrying out the assay in our 
laboratory include, clients travelling from far to 
Lagos, limited shelf life of the reagents in the kits, 
delay in kit supply from Germany, electronic 
payment of the test by some clients amongst 
others. It is therefore suggested that there be put 
in place a national programme to mitigate the 
scourge of the virus which is a hundred times 
more infectious than HIV. Taiwan and Saudi 
Arabia have seen the tremendous impact of a 
mass programme of HBV immunization and the 
integration of HBV vaccine in the Expanded 
Programme of Immunization (EPI) in controlling 
HBV infectivity in their general population [17]. 
This is a route which Nigeria might well 




In conclusion, given the high viral load observed 
in this study group and the risk of HCC 
involved, it is recommended that there be health 
education for public and health care providers. 
Also screening and vaccination of all special risk 
groups especially surgeons, laboratory workers, 
dentists, emergency workers and law 
enforcement agents. A comprehensive effort is 
needed to promote hepatitis B testing in the 
Nigerian population, with community outreach, 
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